North Carolina 2017-2018 Session Status: Enacted Bipartisan · 22 R · 12 D cosponsors

HB 243 — Strengthen Opioid Misuse Prevention (STOP)Act.

Last action — Signed by Gov. 6/29/2017

Track this bill free

No card. One bill, free forever — alerts when it moves.

  1. ✓
    Introduced
  2. ✓
    In Committee
  3. ✓
    Passed House
  4. ✓
    Passed Senate
  5. ✓
    To Executive
  6. 6
    Enacted

This bill has been enacted into law. Introduced March 02, 2017. Enacted.

Prognosis

Likely to advance 98% · high confidence

Where this bill stands today.

Odds of enactment

High

How often bills like it became law.

  • Enacted

    Current position in the legislative process.

  • 75 sponsors

    3 primary, 72 co-sponsors signed on.

  • Bipartisan support

    Sponsored across 2 parties (22 R · 12 D) — cross-party backing.

  • Cleared a recorded vote

    Passed 2 recorded votes so far.

Prognosis reads this bill's own signals — stage, sponsorship breadth, committee status, recorded votes and cross-state momentum. Odds come from a model trained on which bills have become law.

Bill Text

What changed in the latest version

473 added · 517 removed

Plain-language change summary

The latest version of the STOP Act broadens its focus by including all Schedule II through V controlled substances instead of just Schedule II and III, which is significant as it aims to strengthen oversight and prevention efforts regarding a wider range of potentially misused medications. Additionally, it introduces an annual fee for practitioners to support a special revenue fund for the Controlled Substances Reporting System (CSRS), which could enhance funding for monitoring and prevention initiatives. These changes are aimed at more effectively combating opioid misuse and ensuring better compliance within the healthcare system.

→
Previous
Latest
GENERAL ASSEMBLY OF NORTH CAROLINA SESSION 2017 H 2 HOUSE BILL 243* Committee Substitute Favorable 3/30/17 Short Title:
GENERAL ASSEMBLY OF NORTH CAROLINA SESSION 2017 H 1 HOUSE BILL 243* Short Title:Strengthen Opioid Misuse Prevention (STOP)Act.
Strengthen Opioid Misuse Prevention (STOP)Act.
Referred to:
Representatives Murphy, Davis, Malone, and Horn (Primary Sponsors).
March 6, 2017 A BILL TO BE ENTITLED AN ACT STRENGTHENING OPIOID MISUSE PREVENTION BY EXTENDING STANDING ORDERS FOR OPIOID ANTAGONIST TO COMMUNITY HEALTH GROUPS;
For a complete list of sponsors, refer to the North Carolina General Assembly web site.
REQUIRING SUPERVISING PHYSICIANS TO PERSONALLY CONSULT WITH PHYSICIAN ASSISTANTS AND NURSE PRACTITIONERS WHO PRESCRIBE CERTAIN SCHEDULE II OR III CONTROLLED SUBSTANCES FOR LONG-TERM USE;
Referred toHealth, if favorable, Appropriations March 6, 2017 A BILL TO BE ENTITLED AN ACT STRENGTHENING OPIOID MISUSE PREVENTION BY EXTENDING STANDING ORDERS FOR OPIOID ANTAGONIST TO COMMUNITY HEALTH GROUPS;
REQUIRING ELECTRONIC PRESCRIBING OF CERTAIN SCHEDULE II AND III CONTROLLED SUBSTANCES;
REQUIRING SUPERVISING PHYSICIANS TO PERSONALLY CONSULT WITH PHYSICIAN ASSISTANTS AND NURSE PRACTITIONERS WHO PRESCRIBE SCHEDULE II THROUGH V CONTROLLED SUBSTANCES FOR LONG-TERM USE;
ESTABLISHING MAXIMUM LIMITS FOR INITIAL PRESCRIPTIONS OF CERTAIN SCHEDULE II AND III CONTROLLED SUBSTANCES;
REQUIRING ELECTRONIC PRESCRIBING OF SCHEDULE II THROUGH V CONTROLLED SUBSTANCES;
REQUIRING HOSPICE AND PALLIATIVE CARE PROVIDERS TO PROVIDE EDUCATION REGARDING PROPER DISPOSAL OF CERTAIN UNUSED CONTROLLED SUBSTANCES;
ESTABLISHING MAXIMUM LIMITS FOR INITIAL PRESCRIPTIONS OF SCHEDULE II THROUGH V CONTROLLED SUBSTANCES;
AND REQUIRING AN ANNUAL REPORT FROM DHHS ON THE CSRS.
IMPOSING AN ANNUAL FEE ON PRACTITIONERS TO BE DEPOSITED INTO THE CSRS SPECIAL REVENUE FUND;
REQUIRING AN ANNUAL REPORT FROM DHHS ON THE CSRS;
AND APPROPRIATING FUNDS FOR COMMUNITY-BASED SUBSTANCE USE DISORDER TREATMENT AND RECOVERY SERVICES.
(a) As used in this section, "opioid antagonist" means naloxone hydrochloride that is approved by the federal Food and Drug Administration for the treatment of a drug overdose.
*H243-v-1* General Assembly Of North Carolina Session 2017 (a) As used in this section, "opioid antagonist" means naloxone hydrochloride that is approved by the federal Food and Drug Administration for the treatment of a drug overdose.
*H243-v-2* General Assembly Of North Carolina Session 2017 (b) The following individuals may prescribe an opioid antagonist in the manner prescribed by this subsection:
(b) The following individuals may prescribe an opioid antagonist in the manner prescribed by this subsection:
Evidence of the use of reasonable Page 2 House Bill 243*-Second Edition General Assembly Of North Carolina Session 2017 care in administering the drug shall include the receipt of basic instruction and information on how to administer the opioid antagonist.
Evidence of the use of reasonable care in administering the drug shall include the receipt of basic instruction and information on how to administer the opioid antagonist.
(e) All of the following individuals are immune from any civil or criminal liability for actions authorized by this section:
Page 2 House Bill 243*-First Edition General Assembly Of North Carolina Session 2017 (e) All of the following individuals are immune from any civil or criminal liability for actions authorized by this section:
90-87 reads as rewritten:
"§ 90-87.
Definitions.
As used in this Article:
… (26a) "Targeted controlled substance" means any controlled substance included in G.S.
90-90 (1), (2), or (3) or G.S.
90-91(d).
…." SECTION 4.
G.S.
"(5) If the prescription is for a targeted controlled substance as defined in Article 5 of Chapter 90 of the General Statutes and therapeutic use of the targeted controlled substance will or is expected to exceed a period of 30 days, the physician assistant shall personally consult with the supervising physician prior to prescribing the targeted controlled substance to verify that the prescription is medically appropriate for the patient.
"(5) If the prescription is for a controlled substance included in Schedule II through V of Article 5 of Chapter 90 of the General Statutes and therapeutic use of the controlled substance will or is expected to exceed a period of 30 days, the physician assistant shall personally consult with the supervising physician prior to prescribing the controlled substance to verify that the prescription is medically appropriate for the patient.
For as long as a targeted controlled substance is continuously prescribed to the same patient, the physician assistant shall consult with the supervising physician at least once every 90 days to verify that the prescription remains medically appropriate for the patient." SECTION 5.
For as long as a Schedule II through V controlled substance is continuously prescribed to the same patient, the physician assistant shall consult with the supervising physician at least once every 90 days to verify that the prescription remains medically appropriate for the patient." SECTION 4.
"(5) If the prescription is for a targeted controlled substance as defined in Article 5 of Chapter 90 of the General Statutes and therapeutic use of the targeted controlled substance will or is expected to exceed a period of 30 days, the nurse practitioner shall personally consult with the supervising physician prior to prescribing the targeted controlled substance to verify that the prescription is medically appropriate for the patient.
"(5) If the prescription is for a controlled substance included in Schedule II through V of Article 5 of Chapter 90 of the General Statutes and therapeutic use of the controlled substance will or is expected to exceed a period of 30 days, the nurse practitioner shall personally consult with the supervising physician prior to prescribing the controlled substance to verify that the prescription is medically appropriate for the patient.
For as long as a targeted controlled substance is continuously prescribed to the same patient, the nurse practitioner shall consult with the supervising physician at least once every 90 days to verify that the prescription remains medically appropriate for the patient." SECTION 6.
For as long as a Schedule II through V controlled substance is continuously prescribed to the same patient, the nurse practitioner shall consult with the supervising physician at least once every 90 days to verify that the prescription remains medically appropriate for the patient." SECTION 5.
House Bill 243*-Second Edition Page 3 General Assembly Of North Carolina Session 2017 (a1) Electronic Prescription Required;
(a1) Unless otherwise exempted by this subsection, a practitioner shall electronically prescribe all controlled substances included in Schedule II through V of this Article.
Exceptions.
This subsection does not apply to prescriptions for Schedule II through V controlled substances issued by any of the following:
– Unless otherwise exempted by this subsection, a practitioner shall electronically prescribe all targeted controlled substances.
This subsection does not apply to prescriptions for targeted controlled substances issued by any of the following:
(3) A practitioner who experiences temporary technological or electrical failure or other extenuating circumstance that prevents the prescription from being transmitted electronically, provided, however, that the practitioner documents the reason for this exception in the patient's medical record.
House Bill 243*-First Edition Page 3 General Assembly Of North Carolina Session 2017 (3) A practitioner who experiences temporary technological or electrical failure that prevents the prescription from being transmitted electronically;
(4) A practitioner who writes a prescription to be dispensed by a pharmacy located on federal property, provided, however, that the practitioner documents the reason for this exception in the patient's medical record.
provided, however, that the practitioner documents the reason for this exception in the patient's medical record.
(a2) Verification by Dispenser Not Required.
(4) A practitioner who writes a prescription to be dispensed by a pharmacy located on federal property;
– A dispenser is not required to verify that a practitioner properly falls under one of the exceptions specified in subsection (a1) of this section prior to dispensing a targeted controlled substance.
provided, however, that the practitioner documents the reason for this exception in the patient's medical record.
A dispenser may continue to dispense targeted controlled substances from valid written, oral, or facsimile prescriptions that are otherwise consistent with applicable laws.
(a2) A dispenser is not required to verify that a practitioner properly falls under one of the exceptions specified in subsection (a1) of this section prior to dispensing a controlled substance included in Schedule II through V of this Article.
(a3) Limitation on Prescriptions Upon Initial Consultation for Acute Pain.
A dispenser may continue to dispense controlled substances included in Schedules II through V of this Article from valid written, oral, or facsimile prescriptions that are otherwise consistent with applicable laws.
– A practitioner may not prescribe more than a five-day supply of any targeted controlled substance upon the initial consultation and treatment of a patient for acute pain, unless the prescription is for post-operative acute pain relief for use immediately following a surgical procedure.
(a3) A practitioner may not prescribe more than a five-day supply of any controlled substance included in Schedule II through V of this Article upon the initial consultation and treatment of a patient for acute pain, unless the prescription is for immediate post-operative pain relief.
A practitioner shall not prescribe more than a seven-day supply of any targeted controlled substance for post-operative acute pain relief immediately following a surgical procedure.
A practitioner may not prescribe more than a seven-day supply of any controlled substance included in Schedule II through V of this Article for immediate post-operative pain relief.
Show all 139 changed rows (99 more)
Previous
Latest
Upon any subsequent consultation for the same pain, the practitioner may issue any appropriate renewal, refill, or new prescription for a targeted controlled substance.
Upon any subsequent consultation for the same pain, the practitioner may issue any appropriate renewal, refill, or new prescription for a Schedule II through V controlled substance.
This subsection does not apply to prescriptions for controlled substances issued by a practitioner who orders a controlled substance to be wholly administered in a hospital, nursing home licensed under Chapter 131E of the General Statutes, hospice facility, or residential care facility as defined in G.S.
(a4) As used in this subsection, the following terms have the following meanings:
14-32.2(c1).
(a4) Definitions.
– As used in this subsection, the following terms have the following meanings:
(3) Surgical procedure.
– A procedure that is performed for the purpose of structurally altering the human body by incision or destruction of tissues as part of the practice of medicine.
This term includes the diagnostic or therapeutic treatment of conditions or disease processes by use of instruments such as lasers, ultrasound, ionizing, radiation, scalpels, probes, or needles that cause localized alteration or transportation of live human tissue by cutting, burning, vaporizing, freezing, suturing, probing, or manipulating by closed reduction for major dislocations and fractures, or Page 4 House Bill 243*-Second Edition General Assembly Of North Carolina Session 2017 otherwise altering by any mechanical, thermal, light-based, electromagnetic, or chemical means.
(a5) Dispenser Immunity.
– A dispenser shall be immune from any civil or criminal liability or disciplinary action from the Board of Pharmacy for dispensing a prescription written by a prescriber in violation of this section.
(i) A manufacturer's sales representative may distribute a controlled substance as a complimentary sample only upon the written request of a practitioner.
Page 4 House Bill 243*-First Edition General Assembly Of North Carolina Session 2017 (i) A manufacturer's sales representative may distribute a controlled substance as a complimentary sample only upon the written request of a practitioner.
The manufacturer shall maintain a record of each such request for a period of two years." SECTION 7.
The manufacturer shall maintain a record of each such request for a period of two years." SECTION 6.
Any hospice or palliative care provider who prescribes a targeted controlled substance to be administered to a patient in his or her home for the treatment of pain as part of in-home hospice or palliative care shall, at the commencement of treatment, provide oral and written information to the patient and his or her family regarding the proper disposal of such targeted controlled substances.
Any hospice or palliative care provider who prescribes a controlled substance included in Schedule II through V of this Article to be administered to a patient in his or her home for the treatment of pain as part of in-home hospice or palliative care shall make diligent efforts to ensure that any residual portion of the controlled substance is safely disposed of following the death of the patient.
This information shall include the availability of permanent drop boxes or periodic "drug take-back" events that allow for the safe disposal of controlled substances such as those permanent drop boxes and events that may be identified through North Carolina Operation Medicine Drop." PART IV.
The hospice or palliative care provider shall comply with all applicable State and federal laws in carrying out the requirements of this section." SECTION 7.
Article 51 of Chapter 58 of the General Statutes is amended by adding a new section to read:
"§ 58-51-56.
Limitation on co-payments for limited, initial opioid prescriptions.
Every health benefit plan delivered or issued for delivery in this State that provides coverage for prescription drugs subject to co-payment shall charge a co-payment for a limited, initial prescription of a Schedule II through V controlled substance prescribed in accordance with G.S.
90-106(a3) in an amount that is (i) proportional between the co-payment charged for a 30-day supply of the controlled substance and the amount of the controlled substance prescribed to the beneficiary or (ii) equivalent to the co-payment for a 30-day supply of the controlled substance;
provided, however, that the health benefit plan shall not subject the beneficiary to any additional co-payments for any additional prescriptions of the same controlled substance for the remainder of the 30-day supply." PART IV.
House Bill 243*-Second Edition Page 5 General Assembly Of North Carolina Session 2017 "(2) Needles, hypodermic syringes, and other injection supplies at no cost and in quantities sufficient to ensure that needles, hypodermic syringes, and other injection supplies are not shared or reused.
"(2) Needles, hypodermic syringes, and other injection supplies at no cost and in quantities sufficient to ensure that needles, hypodermic syringes, and other injection supplies are not shared or reused.
No public State funds may be used to purchase needles, hypodermic syringes, or other injection supplies." 6 PART V.
No public State funds may be used to purchase needles, hypodermic syringes, or other injection supplies." PART V.
(2) "Controlled substance" means a Controlled substance.
(2) "Controlled substance" means a Controlled Substance.
b.
House Bill 243*-First Edition Page 5 General Assembly Of North Carolina Session 2017 b.
however, dispensers are encouraged to report the information no later than 24 hoursthe close of the next business day after the prescription is delivered;
The information shall be submitted in a format as determined annually by the Department based on the format used in Page 6 House Bill 243*-Second Edition General Assembly Of North Carolina Session 2017 the majority of the states operating a controlled substances reporting system.
The information shall be submitted in a format as determined annually by the Department based on the format used in the majority of the states operating a controlled substances reporting system.
In the event the dispenser is unable to report the information within the time frame required by this section because the system is not operational or there is some other temporary electrical or technological failure, this inability shall be documented in the dispenser's records.
Once the electrical or technological failure has been resolved, the dispenser shall promptly report the information.
or if the controlled substance is dispensed for an animal, the name of the owner of the animal and the following information of the patient or owner:
(12) If the prescriber is a physician assistant or a nurse practitioner, the name of that individual's supervising physician.
(e) The Department shall assess, against any pharmacy that employs dispensers found to have failed to report information in the manner required by this section within a reasonable period of time after being informed by the Department that the required information is missing or incomplete, a civil penalty of not more than one hundred dollars ($100.00) for a first violation, two hundred fifty dollars ($250.00) for a second violation, and five hundred dollars ($500.00) for each subsequent violation if the pharmacy fails to report as required under this section, up to a maximum of five thousand dollars ($5,000) per pharmacy per calendar year.
Page 6 House Bill 243*-First Edition General Assembly Of North Carolina Session 2017 (e) The Department shall assess, against any pharmacy that employs dispensers found to have failed to report information in the manner required by this section within a reasonable period of time after being informed by the Department that the required information is missing or incomplete, a civil penalty of not more than two hundred fifty dollars ($250.00) for a first violation and five hundred dollars ($500.00) for each subsequent violation if the pharmacy fails to report as required under this section, up to a maximum of ten thousand dollars ($10,000) per pharmacy per calendar year.
… House Bill 243*-Second Edition Page 7 General Assembly Of North Carolina Session 2017 (1a) Notify practitioners and their respective licensing boards of prescribing behavior that (i) increases risk of diversion of controlled substances, (ii) increases risk of harm to the patient, or (iii) is an outlier among other practitioner behavior.
...
…." SECTION 12.
(1a) Notify practitioners of prescribing behavior that (i) increases risk of diversion of controlled substances, (ii) increases risk of harm to the patient, or (iii) is an outlier among other practitioner behavior.
...." SECTION 12.
G.S.
90-113.74(c) reads as rewritten:
"(c) The Department shall release data in the controlled substances reporting system to the following persons only:
...
(11) Any third-party payer or pharmacy benefits manager acting as agent of a third-party payer, for the purposes of (i) claimant case management, (ii) detection of inappropriate prescribing of a controlled substance to a claimant, or (iii) detection of misuse or diversion of a controlled substance by a claimant." SECTION 13.
"§ 90-113.74B.
"§ 90-113.74A.
Mandatory dispenser registration for access to controlled substances reporting system;
Mandatory dispenser registration for access to controlled substances reporting system.
exception.
Within 30 days after obtaining an initial or renewal license to practice pharmacy, the licensee shall demonstrate to the satisfaction of the North Carolina Board of Pharmacy that he or she is registered for access to the controlled substances reporting system.
(a) Within 30 days after obtaining an initial or renewal license to practice pharmacy, the licensee shall demonstrate to the satisfaction of the North Carolina Board of Pharmacy that he or she is registered for access to the controlled substances reporting system.
(b) This section does not apply to a licensee employed in a pharmacy practice setting where a Schedule II, III, or IV controlled substance will not be dispensed.
"§ 90-113.74B.
"§ 90-113.74C.
(a) Prior to initially prescribing a targeted controlled substance to a patient, a practitioner shall review the information in the controlled substances reporting system pertaining to the patient for the 12-month period preceding the initial prescription.
(a) Prior to initially prescribing a Schedule II through V controlled substance to a patient, a practitioner shall review the information in the controlled substances reporting system pertaining to the patient for the 12-month period preceding the initial prescription.
For every subsequent three-month period that the targeted controlled substance remains a part of the patient's medical care, the practitioner shall review the information in the controlled substances reporting system pertaining to the patient for the 12-month period preceding the determination that the targeted controlled substance should remain a part of the patient's medical care.
For every subsequent three-month period that the controlled substance remains a part of the patient's medical care, the practitioner shall review the information in the controlled substances reporting system pertaining to the patient for the 12-month period preceding the determination that the controlled substance should remain a part of the patient's medical care.
In the event the practitioner is unable to review the information in the controlled substances reporting system pertaining to the patient because the system is not operational or there is some other temporary electrical or technological failure, this inability shall be documented in the patient's medical record.
In the event the practitioner is unable to review the information in the controlled substances reporting system pertaining to the patient because the system is not operational or there is some other electrical or technological failure, this inability shall be documented in the patient's medical record.
Once the electrical or technological failure has been resolved, the practitioner shall review the information in the controlled substances reporting system pertaining to the patient and the review shall be documented in the patient's medical record.
Once the electrical or technological failure has been resolved, the practitioner shall review the information in the controlled substances House Bill 243*-First Edition Page 7 General Assembly Of North Carolina Session 2017 reporting system pertaining to the patient and the review shall be documented in the patient's medical record.
(b) A practitioner may, but is not required to, review the information in the controlled substances reporting system pertaining to a patient prior to prescribing a targeted controlled substance to the patient in any of the following circumstances:
(b) A practitioner may, but is not required to, review the information in the controlled substances reporting system pertaining to a patient prior to prescribing a Schedule II through V controlled substance to the patient in any of the following circumstances:
(4) The controlled substance is prescribed in an amount indicated for a period not to exceed five days and does not allow a refill, or for a period not to exceed seven days if the prescription indicates the controlled substance is for immediate post-operative pain relief.
"§ 90-113.74D.
"§ 90-113.74C.
(a) Prior to dispensing a targeted controlled substance, a dispenser shall review the information in the controlled substances reporting system pertaining to the patient for the Page 8 House Bill 243*-Second Edition General Assembly Of North Carolina Session 2017 preceding 12-month period and document this review under any of the following circumstances:
(a) Prior to dispensing a Schedule II through V controlled substance, a dispenser shall review the information in the controlled substances reporting system pertaining to the patient for the preceding 12-month period and document this review whenever:
(1) The dispenser has a reasonable belief that the ultimate user may be seeking a targeted controlled substance for any reason other than the treatment of the ultimate user's existing medical condition.
(1) The dispenser has a reasonable belief that the ultimate user may be seeking a Schedule II through V controlled substance for any reason other than the treatment of the ultimate user's existing medical condition.
(b) If a dispenser has reason to believe a prescription for a targeted controlled substance is fraudulent or duplicative, the dispenser shall withhold delivery of the prescription until the dispenser is able to contact the prescriber and verify that the prescription is medically appropriate.
(b) If a dispenser has reason to believe a prescription for a Schedule II through V controlled substance is fraudulent or duplicative, the dispenser shall withhold delivery of the prescription until the dispenser is able to contact the prescriber and verify that the prescription is medically appropriate.
(c) A dispenser shall be immune from any civil or criminal liability for actions authorized by this section.
A dispenser shall be immune from any civil or criminal liability for actions authorized by this subsection.
Failure to review the system in accordance with subsection (a) of this section shall not constitute medical negligence.
(a) The Controlled Substances Reporting System Fund is created within the Department as a special revenue fund.
Page 8 House Bill 243*-First Edition General Assembly Of North Carolina Session 2017 (a) The Controlled Substances Reporting System Fund is created within the Department as a special revenue fund.
(1) Any moneys appropriated to the Fund by the General Assembly.
(1) Moneys transmitted to the Fund pursuant to G.S.
(2) Any moneys received from State, federal, private, or other sources for deposit into the Fund.
90-113.75B.
(2) Any moneys appropriated to the Fund by the General Assembly.
(3) Any moneys received from State, federal, private, or other sources for deposit into the Fund.
Controlled substances reporting system fee.
(a) Beginning January 1, 2018, each licensing board authorized to issue an initial or renewal license that confers upon the licensee the authority to prescribe a controlled substance for the purpose of providing medical care for a patient shall impose an annual controlled substances reporting system fee in the amount of twenty dollars ($20.00) on the licensee.
This fee shall be in addition to any other initial or renewal license fee the licensing board is authorized to collect from the licensee under Chapter 90 of the General Statutes.
The licensing board shall collect the fee required by this subsection at the same time it collects the initial or renewal license fee imposed on the licensee.
Each licensing board shall retain ten percent (10%) of the total amount of moneys collected for the controlled substances reporting system fee pursuant to this subsection to cover the costs incurred by the licensing board for collecting and providing an accounting of all moneys received as payment of this fee.
On the first day of each calendar quarter, each licensing board shall transmit ninety percent (90%) of the total amount of moneys collected pursuant to this subsection during the preceding calendar quarter to the Controlled Substances Reporting System Fund created in G.S.
90-113.75A.
(b) This section shall not be construed to apply to an individual licensed to practice veterinary medicine pursuant to Article 11 of Chapter 90 of the General Statutes.
"§ 90-113.75C.
Annually on February 1, beginning February 1, 2019, the Department shall report to the Joint Legislative Oversight Committee on Health and Human Services, the North Carolina Medical Board, the North Carolina Board of Podiatry Examiners, the North Carolina Board of Nursing, the North Carolina Dental Board, the North Carolina Veterinary Medical Board, and the North Carolina Board of Pharmacy on data reported to the controlled substances reporting system.
Annually on November 1, beginning November 1, 2018, the Department shall report to the Joint Legislative Oversight Committee on Health and Human Services, the North Carolina Medical Board, the North Carolina Board of Nursing, the North Carolina Dental Board, the North Carolina Veterinary Medical Board, and the North Carolina Board of Pharmacy on data reported to the controlled substances reporting system.
The report shall include at least all of the following information about targeted controlled substances reported to the system during the preceding calendar year:
The report shall include at least all of the following information about Schedule II through V controlled substances reported to the system during the preceding calendar year:
House Bill 243*-Second Edition Page 9 General Assembly Of North Carolina Session 2017 (4) The number of ultimate users who were prescribed a controlled substance by two or more practitioners.
(4) The number of ultimate users who were prescribed a controlled substance by two or more practitioners.
For the purpose of this subdivision, medical doctors, surgeons, palliative care practitioners, oncologists and other practitioners specializing in oncology, pain management practitioners, practitioners who specialize in hematology, including the treatment of sickle cell disease, and practitioners who specialize in treating substance use disorder shall be treated as distinct categories of practitioners.
For the purpose of this subdivision, medical doctors and surgeons shall be treated as distinct categories of practitioners.
(7) Any other data deemed appropriate and requested by the Joint Legislative Oversight Committee on Health and Human Services, the North Carolina Medical Board, the North Carolina Board of Nursing, the North Carolina Dental Board, the North Carolina Veterinary Medical Board, or the North Carolina Board of Pharmacy." SECTION 13.(a) Section 12F.16(h) of Session Law 2015-241 reads as rewritten:
(7) Prescribing behavior of practitioners that (i) increases risk of diversion of controlled substances, (ii) increases risk of harm to the patient, or (iii) is an outlier among other practitioner behavior.
"SECTION 12F.16.(h) The Department of Health and Human Services, Division of Mental Health, Developmental Disabilities, and Substance Abuse Services (DHHS), shall continue to work toward establishing interstate connectivity for the Controlled Substances Reporting System (CSRS) established under G.S.
House Bill 243*-First Edition Page 9 General Assembly Of North Carolina Session 2017 (8) Any other data deemed appropriate and requested by the Joint Legislative Oversight Committee on Health and Human Services, the North Carolina Medical Board, the North Carolina Board of Nursing, the North Carolina Dental Board, the North Carolina Veterinary Medical Board, or the North Carolina Board of Pharmacy." 7 PART VI.
90-113.73.
APPROPRIATION FOR COMMUNITY-BASED SUBSTANCE USE DISORDER TREATMENT AND RECOVERY SERVICES SECTION 14.
DHHS shall apply for grant funding from the National Association of Boards of Pharmacy to establish the connection to PMP InterConnect.interstate connectivity for the CSRS.
There is appropriated from the General Fund to the Department of Health and Human Services, Division of Mental Health, Developmental Disabilities, and Substance Abuse Services, the sum of ten million dollars ($10,000,000) for the 2017-2018 fiscal year and the sum of ten million dollars ($10,000,000) for the 2018-2019 fiscal year.
The Department shall request forty thousand thirty-five dollars ($40,035) to establish the initial interface for PMP InterConnectinterstate connectivity for the CSRS and thirty thousand dollars ($30,000) for two years of ongoing interstate connectivity service, maintenance, and support for PMP InterConnect in order to create interstate connectivity for the drug monitoring program as required by subdivision (2) of subsection (f) of this section.support." SECTION 13.(b) Section 12F.16(i)(3) of Session Law 2015-241 reads as rewritten:
These funds shall not be used for any purpose other than to increase the availability of community-based treatment and recovery services for substance use disorders, including medication-assisted treatment.
"(3) For the 2015-2016 fiscal year, the sum of forty thousand thirty-five dollars ($40,035) shall be used to establish the initial interface for PMP InterConnect, interstate connectivity for the CSRS, as required by subdivision (2) of subsection (f) of this section.
These funds shall not supplant existing funds for community-based treatment and recovery services for substance use disorders.
This amount shall be adjusted or eliminated if DHHS is successful in obtaining grant awards or identifying other allowable receipts for this purpose.
PART VII.
If receipts are used for this purpose, this nonrecurring appropriation shall revert to the General Fund.
EFFECTIVE DATE SECTION 15.(a) Sections 1, 2, 3, 4, 6, 8, and 14 of this act become effective July 1, 2017.
Upon receipt of any grant funding used for this purpose or upon identification of other allowable receipts for this purpose, DHHS shall reimburse the General Fund for the costs associated with establishing interstate connectivity for the CSRS.
SECTION 15.(b) Sections 5 and 7 of this act become effective July 1, 2018.
The reimbursement amount shall be limited to the amount of any grant funding received by DHHS for this purpose plus the amount of any allowable receipts used by DHHS for this purpose, but shall not exceed the amount of the nonrecurring funds appropriated in this section." PART VI.
SECTION 15.(c) G.S.
EFFECTIVE DATE SECTION 14.(a) Sections 1, 2, 3, 4, 5, 7, 8, 11, and 13 of this act become effective July 1, 2017.
90-113.75A through G.S.
Page 10 House Bill 243*-Second Edition General Assembly Of North Carolina Session 2017 SECTION 14.(b) Subsections (a), (a1), and (a2) of G.S.
90-113.75C, as enacted by Section 13 of this act, become effective September 1, 2017.
90-106, as amended by Section 6 of this act, become effective January 1, 2020.
SECTION 15.(d) The remainder of this act is effective when it becomes law and applies to acts committed on or after the date the State Chief Information Officer notifies the Revisor of Statutes that (i) the upgrades to the Controlled Substances Reporting System (CSRS) database described in subdivisions (1) and (2) of subsection (a) of Section 12F.7 of S.L.
SECTION 14.(c) Subsections (a3) and (a4) of G.S.
90-106, as amended by Section 6 of this act, become effective January 1, 2018.
SECTION 14.(d) G.S.
90-113.75A and G.S.
90-113.75B, as enacted by Section 12 of this act, become effective September 1, 2017.
SECTION 14.(e) Subsection (b) of G.S.
90-113.73(b), as enacted by Section 10 of this act, is effective when it becomes law.
The remainder of Section 10 of this act becomes effective 30 days after the date the Chief Information Officer notifies the Revisor of Statutes that the Controlled Substance Reporting System (CSRS) database has the capability to record the information described in Section 10 of this act.
The Chief Information Officer shall notify the Revisor of Statutes once the CSRS database has the capability to record the information described in Section 10 of this act.
SECTION 14.(f) The remainder of this act is effective when it becomes law and applies to acts committed 30 days after the date the State Chief Information Officer notifies the Revisor of Statutes that (i) the upgrades to the Controlled Substances Reporting System (CSRS) database described in subdivisions (1) and (2) of subsection (a) of Section 12F.7 of S.L.
House Bill 243*-Second Edition Page 11
Page 10 House Bill 243*-First Edition
⬇ Download PDF
View plain text versions (11)

Action History

  1. Signed by Gov. 6/29/2017

  2. Ch. SL 2017-74

  3. Ratified

  4. Pres. To Gov. 6/28/2017

  5. Concurred In S/Com Sub

  6. Ordered Enrolled

  7. Cal Pursuant 36(b)

  8. Added to Calendar

  9. Withdrawn From Cal

  10. Placed On Cal For 06/27/2017

  11. Regular Message Sent To House

  12. Regular Message Received For Concurrence in S Com Sub

  13. Amend Adopted A1

  14. Passed 2nd Reading

  15. Passed 3rd Reading

  16. Engrossed

  17. Reptd Fav

  18. Reptd Fav Com Substitute

  19. Com Substitute Adopted

  20. Re-ref Com On Rules and Operations of the Senate

  21. Withdrawn From Com

  22. Re-ref to Health Care. If fav, re-ref to Rules and Operations of the Senate

  23. Regular Message Sent To Senate

  24. Regular Message Received From House

  25. Passed 1st Reading

  26. Ref To Com On Rules and Operations of the Senate

  27. Amend Adopted A1

  28. Amend Adopted A2

  29. Amend Failed A3

  30. Passed 2nd Reading

  31. Passed 3rd Reading

  32. Ordered Engrossed

  33. Withdrawn From Com

  34. Cal Pursuant Rule 36(b)

  35. Placed On Cal For 04/10/2017

  36. Reptd Fav Com Substitute

  37. Re-ref Com On Appropriations

  38. Passed 1st Reading

  39. Ref to the Com on Health, if favorable, Appropriations

  40. Filed

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

3 sponsors · 72 co-sponsors · 104 not signed on

Sponsors (3)

Co-sponsors (72)

Not signed on (104)

104 members have not signed on to this bill.

Show all 104 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Votes

M11 Concur

Passed 118 Yea · 0 Nay · 2 Other
Party YeaNayPresentNot Voting
Unaffiliated 75001
Democratic 15000
Republican 28000
U 0001
Total 118002
% of votes cast 98%0%0%2%
How each member voted (120)
Member Party Vote
McElraft — Yea
Michaux — Yea
Millis — Yea
Szoka — Yea
Terry — Yea
Williams — Yea
Zachary — Yea
Autry — Yea
Black — Yea
Boles — Yea
Boswell — Yea
Burr — Yea
Conrad — Yea
Dobson — Yea
Faircloth — Yea
Farmer-Butterfield — Yea
Fisher — Yea
Floyd — Yea
Fraley — Yea
Garrison — Yea
Gill — Yea
G.Adcock — Yea
L.Bell — Yea
Beasley — Yea
DuaneHall — Yea
C.Graham — Yea
G.Graham — Yea
Jackson — Yea
G.Martin — Yea
R.Moore — Yea
B.Richardson — Yea
W.Richardson — Yea
B.Turner — Yea
J.Bell — Yea
BertJones — Yea
Brawley — Yea
DestinHall — Yea
K.Hall — Yea
Johnson — Yea
Bradford — Yea
Bumgardner — Yea
Cleveland — Yea
Collins — Yea
Dollar — Yea
Dulin — Yea
Earle — Yea
Elmore — Yea
Goodman — Yea
Grange — Yea
Hanes — Yea
Hardister — Yea
Henson — Yea
Holley — Yea
Horn — Yea
Hunter — Yea
Hurley — Yea
Insko — Yea
Jordan — Yea
Lewis — Yea
Lucas — Yea
Wray — Yea
Malone — Yea
S.Martin — Yea
T.Moore(Speaker) — Yea
Stone — Yea
R.Turner — Yea
BrendenJones — Not Voting
McGrady — Yea
McNeill — Yea
Murphy — Yea
Presnell — Yea
Rogers — Yea
Saine — Yea
Speciale — Yea
Steinburg — Yea
Yarborough — Yea
Amos L. Quick, III Democratic Yea
Becky Carney Democratic Yea
Cecil Brockman Democratic Yea
Cynthia Ball Democratic Yea
Dante Pittman Democratic Yea
Deb Butler Democratic Yea
Eric Ager Democratic Yea
Garland E. Pierce Democratic Yea
Graig Meyer Democratic Yea
Joe John Democratic Yea
Marcia Morey Democratic Yea
Mary Belk Democratic Yea
Pricey Harrison Democratic Yea
Robert T. Reives, II Democratic Yea
Shelly Willingham Democratic Yea
Carl Ford Republican Yea
Dean Arp Republican Yea
Dennis Riddell Republican Yea
Donna McDowell White Republican Yea
Donny Lambeth Republican Yea
Frank Iler Republican Yea
Harry Warren Republican Yea
Hugh Blackwell Republican Yea
Jay Adams Republican Yea
Jimmy Dixon Republican Yea
John A. Torbett Republican Yea
John M. Blust Republican Yea
John Sauls Republican Yea
Julia C. Howard Republican Yea
Kelly E. Hastings Republican Yea
Kevin Corbin Republican Yea
Larry C. Strickland Republican Yea
Larry W. Potts Republican Yea
Mark Brody Republican Yea
Mike Clampitt Republican Yea
Mitchell S. Setzer Republican Yea
Phil Shepard Republican Yea
Sam Watford Republican Yea
Sarah Stevens Republican Yea
Stephen M. Ross Republican Yea
Ted Davis, Jr. Republican Yea
W. Ted Alexander Republican Yea
William D. Brisson Republican Yea
Carla D. Cunningham U Not Voting

Official roll call →

Second Reading

Passed 50 Yea · 0 Nay
Party YeaNayPresentNot Voting
Republican 10000
Unaffiliated 33000
Democratic 7000
Total 50000
% of votes cast 100%0%0%0%
How each member voted (50)
Member Party Vote
McKissick — Yea
Randleman — Yea
Tarte — Yea
Tillman — Yea
Woodard — Yea
Barefoot — Yea
Brock — Yea
Foushee — Yea
D.Davis — Yea
J.Jackson — Yea
Smith — Yea
VanDuyn — Yea
Brown — Yea
J.Davis — Yea
B.Jackson — Yea
Newton — Yea
Tucker — Yea
Ballard — Yea
Barringer — Yea
Bishop — Yea
Bryant — Yea
Curtis — Yea
Dunn — Yea
Edwards — Yea
Gunn — Yea
Harrington — Yea
Horner — Yea
Krawiec — Yea
Meredith — Yea
Pate — Yea
Rabin — Yea
Wade — Yea
Wells — Yea
Amanda P. Cook Democratic Yea
Dan Blue Democratic Yea
Gladys A. Robinson Democratic Yea
Jay J. Chaudhuri Democratic Yea
Joyce Waddell Democratic Yea
Paul A. Lowe, Jr. Democratic Yea
Tracy Clark Democratic Yea
Bill Rabon Republican Yea
Carl Ford Republican Yea
Danny Earl Britt, Jr. Republican Yea
Michael V. Lee Republican Yea
Norman W. Sanderson Republican Yea
Phil Berger Republican Yea
Ralph Hise Republican Yea
Tom McInnis Republican Yea
W. Ted Alexander Republican Yea
Warren Daniel Republican Yea

Official roll call →

Subjects

public-safety healthcare health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

Who sponsors HB 243?
HB 243 is sponsored by Wray, Shelly Willingham (Democratic), Williams, Terry, Larry C. Strickland (Republican), Steinburg, Phil Shepard (Republican), Mitchell S. Setzer (Republican), Dennis Riddell (Republican), Robert T. Reives, II (Democratic), Amos L. Quick, III (Democratic), Presnell, Larry W. Potts (Republican), Murphy, Meyer, McNeill, McGrady, McElraft, Lucas, Donny Lambeth (Republican), Insko, Frank Iler (Republican), Hurley, Julia C. Howard (Republican), Horn, Holley, Henson, Pricey Harrison (Democratic), Gill, Fraley, Floyd, Fisher, Farmer-Butterfield, Faircloth, Dulin, Dollar, Dobson, Jimmy Dixon (Republican), Kevin Corbin (Republican), Cleveland, Deb Butler (Democratic), William D. Brisson (Republican), Bradford, Boswell, Boles, Hugh Blackwell (Republican), Mary Belk (Democratic), Cynthia Ball (Democratic), Malone, Hardister, Hanes, Grange, Goodman, Stone, B. Richardson, S. Martin, Bert Jones, G. Graham, C. Graham, Ford, Becky Carney (Democratic), Kyle Hall (Republican), Neal Jackson (Republican), Brenden H. Jones (Republican), Stephen M. Ross (Republican), Sarah Stevens (Republican), Brian Turner (Democratic), Harry Warren (Republican), Donna McDowell White (Republican), Ted Davis, Jr. (Republican), Jay Adams (Republican), Eric Ager (Democratic), Cecil Brockman (Democratic), Mike Clampitt (Republican), and Joe John (Democratic).
What is the current status of HB 243?
This bill has been enacted into law. Introduced March 02, 2017. Enacted.
Where can I track HB 243?
Track HB 243 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on HB 243

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of HB 243

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →